Radiopharm Theranostics (RADX) Shares Outstanding (Weighted Average) (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Radiopharm Theranostics (RADX) has disclosed Shares Outstanding (Weighted Average) for 2 consecutive years, with $176.6 million as the latest value for Q2 2025.

• Quarterly Shares Outstanding (Weighted Average) rose 75.36% to $176.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $176.6 million through Jun 2025, up 75.36% year-over-year, with the annual reading at $176.6 million for FY2025, 75.36% up from the prior year.
• Shares Outstanding (Weighted Average) for Q2 2025 was $176.6 million at Radiopharm Theranostics, up from $100.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $176.6 million in Q2 2025, with the low at $100.7 million in Q2 2024.

Peer Comparison